

Maureen P M H Rutten-Van Mäjlken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1775959/publications.pdf>

Version: 2024-02-01

236
papers

12,563
citations

47006

47
h-index

29157

104
g-index

245
all docs

245
docs citations

245
times ranked

11806
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis. <i>Value in Health</i> , 2022, 25, 1428-1438. | 0.3 | 13 |
| 2 | Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 501-524. | 2.1 | 19 |
| 3 | Value-based person-centred integrated care for frail elderly living at home: a quasi-experimental evaluation using multicriteria decision analysis. <i>BMJ Open</i> , 2022, 12, e054672. | 1.9 | 5 |
| 4 | Heterogeneity in preferences for outcomes of integrated care for persons with multiple chronic diseases: a latent class analysis of a discrete choice experiment. <i>Quality of Life Research</i> , 2022, 31, 2775-2789. | 3.1 | 1 |
| 5 | Moving Beyond Quality-Adjusted Life-Years in Elderly Care: How Can Multicriteria Decision Analysis Complement Cost-Effectiveness Analysis in Local-Level Decision Making. <i>Value in Health</i> , 2022, 25, 1717-1725. | 0.3 | 3 |
| 6 | Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis. <i>JMIR Cardio</i> , 2022, 6, e31302. | 1.7 | 1 |
| 7 | Economic Evaluation of Integrated Care. , 2021, , 575-593. | | 0 |
| 8 | The impact of the involvement of a healthcare professional on the usage of an eHealth platform: a retrospective observational COPD study. <i>Respiratory Research</i> , 2021, 22, 88. | 3.6 | 12 |
| 9 | Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. <i>Pharmacoeconomics</i> , 2021, 39, 771-788. | 3.3 | 24 |
| 10 | Drivers of successful implementation of integrated care for multi-morbidity: Mechanisms identified in 17 case studies from 8 European countries. <i>Social Science and Medicine</i> , 2021, 277, 113728. | 3.8 | 27 |
| 11 | Bundled payments for chronic diseases increased health care expenditure in the Netherlands, especially for multimorbid patients.. <i>Health Policy</i> , 2021, 125, 751-759. | 3.0 | 10 |
| 12 | Early palliative care associated with lower costs for adults with advanced cancer: evidence from Hungary. <i>European Journal of Cancer Care</i> , 2021, 30, e13473. | 1.5 | 2 |
| 13 | Evaluating Complex Health and Social Care Program Using Multi-Criteria Decision Analysis: A Case Study of "Better Together in Amsterdam North". <i>Value in Health</i> , 2021, 24, 966-975. | 0.3 | 4 |
| 14 | Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study. <i>Value in Health</i> , 2021, 24, 1667-1675. | 0.3 | 3 |
| 15 | Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β_2 -agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. <i>BMJ Open</i> , 2021, 11, e049675. | 1.9 | 3 |
| 16 | Evaluating an integrated care pathway for frail elderly patients in Norway using multi-criteria decision analysis. <i>BMC Health Services Research</i> , 2021, 21, 884. | 2.2 | 4 |
| 17 | Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. <i>Value in Health</i> , 2021, 24, 1435-1445. | 0.3 | 3 |
| 18 | Evaluating Complex Interventions. , 2021, , 611-627. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial. <i>Clinical Nutrition</i> , 2020, 39, 405-413. | 5.0 | 27 |
| 20 | Comparing patients' and other stakeholders' preferences for outcomes of integrated care for multimorbidity: a discrete choice experiment in eight European countries. <i>BMJ Open</i> , 2020, 10, e037547. | 1.9 | 13 |
| 21 | The patient at the centre: evidence from 17 European integrated care programmes for persons with complex needs. <i>BMC Health Services Research</i> , 2020, 20, 1102. | 2.2 | 19 |
| 22 | How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2020, 40, 619-632. | 2.4 | 12 |
| 23 | Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 176. | 2.0 | 1 |
| 24 | The risk of overestimating cost savings from hospital-at-home schemes: A literature review. <i>International Journal of Nursing Studies</i> , 2020, 109, 103652. | 5.6 | 12 |
| 25 | Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients. <i>European Journal of Health Economics</i> , 2020, 21, 557-572. | 2.8 | 13 |
| 26 | Implementation of palliative care consult Service in Hungary – integration barriers and facilitators. <i>BMC Palliative Care</i> , 2020, 19, 41. | 1.8 | 11 |
| 27 | COVID-19 Contact Tracing Apps: Predicted Uptake in the Netherlands Based on a Discrete Choice Experiment. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20741. | 3.7 | 99 |
| 28 | Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. <i>Croatian Medical Journal</i> , 2020, 61, 252-259. | 0.7 | 5 |
| 29 | The disease burden of multimorbidity and its interaction with educational level. <i>PLoS ONE</i> , 2020, 15, e0243275. | 2.5 | 12 |
| 30 | TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. <i>Pharmacoeconomics</i> , 2019, 37, 1391-1408. | 3.3 | 33 |
| 31 | What Is the Potential of Tissue-Engineered Pulmonary Valves in Children?. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1845-1853. | 1.3 | 22 |
| 32 | The Fold-in, Fold-out Design for DCE Choice Tasks: Application to Burden of Disease. <i>Medical Decision Making</i> , 2019, 39, 450-460. | 2.4 | 4 |
| 33 | Exploring the Impact of Adding a Respiratory Dimension to the EQ-5D-5L. <i>Medical Decision Making</i> , 2019, 39, 393-404. | 2.4 | 14 |
| 34 | Evaluation of integrated care services in Catalonia: population-based and service-based real-life deployment protocols. <i>BMC Health Services Research</i> , 2019, 19, 370. | 2.2 | 31 |
| 35 | Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. <i>International Journal of COPD</i> , 2019, Volume 14, 447-456. | 2.3 | 5 |
| 36 | Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. <i>BMC Health Services Research</i> , 2019, 19, 131. | 2.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine. <i>Value in Health</i> , 2019, 22, 313-321. | 0.3 | 14 |
| 38 | Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 2189-2197.e14. | 0.8 | 17 |
| 39 | Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 751-759. | 1.4 | 1 |
| 40 | Digital Health Transformation of Integrated Care in Europe: Overarching Analysis of 17 Integrated Care Programs. <i>Journal of Medical Internet Research</i> , 2019, 21, e14956. | 4.3 | 52 |
| 41 | Integrated Care for Frail Elderly: A Qualitative Study of a Promising Approach in The Netherlands. <i>International Journal of Integrated Care</i> , 2019, 19, 16. | 0.2 | 17 |
| 42 | How much does a heart valve implantation cost and what are the health care costs afterwards?. <i>Open Heart</i> , 2018, 5, e000672. | 2.3 | 19 |
| 43 | Systematic review of model-based economic evaluations of heart valve implantations. <i>European Journal of Health Economics</i> , 2018, 19, 241-255. | 2.8 | 12 |
| 44 | The SELFIE framework for integrated care for multi-morbidity: Development and description. <i>Health Policy</i> , 2018, 122, 12-22. | 3.0 | 149 |
| 45 | Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. <i>Value in Health</i> , 2018, 21, 193-202. | 0.3 | 11 |
| 46 | Relevant models and elements of integrated care for multi-morbidity: Results of a scoping review. <i>Health Policy</i> , 2018, 122, 23-35. | 3.0 | 103 |
| 47 | Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. <i>BMJ Open</i> , 2018, 8, e021072. | 1.9 | 21 |
| 48 | Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013. | 2.5 | 9 |
| 49 | Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA). <i>BMC Health Services Research</i> , 2018, 18, 576. | 2.2 | 43 |
| 50 | Towards incentivising integration: A typology of payments for integrated care. <i>Health Policy</i> , 2018, 122, 963-969. | 3.0 | 51 |
| 51 | Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results. , 2018, , . | | 0 |
| 52 | Clinical outcome and cost-effectiveness of 1-year nutritional intervention program in COPD. , 2018, , . | | 0 |
| 53 | Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. <i>Medical Decision Making</i> , 2017, 37, 453-468. | 2.4 | 24 |
| 54 | Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. <i>Medical Decision Making</i> , 2017, 37, 469-480. | 2.4 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Comparison of cardiovascular risk algorithms in patients with <i>vs</i> without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 777-786. | 1.9 | 28 |
| 56 | External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , 2017, 20, 397-403. | 0.3 | 23 |
| 57 | Comprehensive Diagnostic Assessment of Health Status of Patients with Asthma or COPD: A Delphi Panel Study among Dutch Experts. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 190-199. | 1.6 | 5 |
| 58 | PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 609-619. | 0.5 | 5 |
| 59 | Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. <i>Value in Health</i> , 2017, 20, 1260-1269. | 0.3 | 32 |
| 60 | Assessment of Burden of COPD tool: evidence not perception. <i>European Respiratory Journal</i> , 2017, 50, 1700756. | 6.7 | 0 |
| 61 | Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2017, 37, 440-452. | 2.4 | 21 |
| 62 | Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. <i>Pharmacoeconomics</i> , 2017, 35, 43-63. | 3.3 | 36 |
| 63 | ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs. <i>BMJ Open</i> , 2017, 7, e017831. | 1.9 | 11 |
| 64 | Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes. <i>PLoS ONE</i> , 2017, 12, e0171292. | 2.5 | 0 |
| 65 | Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 179. | 2.7 | 15 |
| 66 | Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , 2017, Volume 12, 3183-3194. | 2.3 | 30 |
| 67 | Evaluating Complex Interventions. , 2017, , 297-313. | | 3 |
| 68 | Common challenges faced in EU-funded projects on integrated care for vulnerable persons. <i>International Journal of Integrated Care</i> , 2017, 17, 17. | 0.2 | 18 |
| 69 | Economic Evaluation of Integrated Care. , 2017, , 315-332. | | 0 |
| 70 | Modeling the cost-effectiveness of stratified medicine in COPD. , 2017, , . | | 0 |
| 71 | Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 927-935. | 3.4 | 10 |
| 72 | A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 135. | 3.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care. <i>BMJ Open</i> , 2016, 6, e011519. | 1.9 | 35 |
| 74 | THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 46-53. | 0.5 | 32 |
| 75 | Conceptual model for early health technology assessment of current and novel heart valve interventions. <i>Open Heart</i> , 2016, 3, e000500. | 2.3 | 20 |
| 76 | Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810. | 0.3 | 11 |
| 77 | Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317. | 3.4 | 27 |
| 78 | Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat [®] fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 391-401. | 2.6 | 15 |
| 79 | “To use or not to use”™: a qualitative study to evaluate experiences of healthcare providers and patients with the assessment of burden of COPD (ABC) tool. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16074. | 2.6 | 8 |
| 80 | Projecting the COPD population and costs in England and Scotland: 2011 to 2030. <i>Scientific Reports</i> , 2016, 6, 31893. | 3.3 | 48 |
| 81 | Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 605-616. | 1.4 | 31 |
| 82 | e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial. <i>European Respiratory Journal</i> , 2016, 48, 758-767. | 6.7 | 54 |
| 83 | The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 431-438. | 1.6 | 19 |
| 84 | Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. <i>Respiratory Medicine</i> , 2016, 110, 34-45. | 2.9 | 18 |
| 85 | Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room. <i>Europace</i> , 2016, 18, 919-924. | 1.7 | 22 |
| 86 | Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. <i>Rheumatology</i> , 2016, 55, 809-816. | 1.9 | 21 |
| 87 | Impact of financial agreements in European chronic care on health care expenditure growth. <i>Health Policy</i> , 2016, 120, 420-430. | 3.0 | 16 |
| 88 | Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements. <i>Calcified Tissue International</i> , 2016, 98, 235-243. | 3.1 | 49 |
| 89 | Performing Economic Evaluation of Integrated Care: Highway to Hell or Stairway to Heaven?. <i>International Journal of Integrated Care</i> , 2016, 16, 3. | 0.2 | 43 |
| 90 | External validation of exacerbation and mortality outcomes of health economic decision models for COPD., 2016, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The assessment of burden of COPD (ABC) tool: What counts most?. , 2016, , . | | 0 |
| 92 | Information exchange between primary care (PC) and secondary care (SC): What is considered important in COPD?. , 2016, , . | | 0 |
| 93 | COPD medication adherence and quality of life. , 2016, , . | | 0 |
| 94 | Exploring the impact of adding a respiratory dimension to the current EQ-5D descriptive system. , 2016, , . | | 0 |
| 95 | What should be part of a comprehensive assessment of COPD?. , 2016, , . | | 0 |
| 96 | The assessment of burden of COPD tool improves health related quality of life. , 2016, , . | | 0 |
| 97 | Prediction models for exacerbations in different COPD patient populations: Results of five large databases. , 2016, , . | | 0 |
| 98 | SELFIE, a novel Horizon2020 project on integrated care for multi-morbidity. International Journal of Integrated Care, 2016, 16, 304. | 0.2 | 0 |
| 99 | Kicking off the Special Interest Group Health Economics in Integrated Care â€œ key questions and actions to move research forward. International Journal of Integrated Care, 2016, 16, 269. | 0.2 | 0 |
| 100 | Exploring the variation in implementation of a COPD disease management programme and its impact on health outcomes: a post hoc analysis of the RECODE cluster randomised trial. Npj Primary Care Respiratory Medicine, 2015, 25, 15071. | 2.6 | 21 |
| 101 | A conceptual disease model for adult Pompe disease. Orphanet Journal of Rare Diseases, 2015, 10, 112. | 2.7 | 10 |
| 102 | Development of an integral assessment approach of health status in patients with obstructive airway diseases: the CORONA study. International Journal of COPD, 2015, 10, 2413. | 2.3 | 18 |
| 103 | Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. PLoS ONE, 2015, 10, e0138225. | 2.5 | 19 |
| 104 | Costs and effects of new professional roles: Evidence from a literature review. Health Policy, 2015, 119, 1176-1187. | 3.0 | 65 |
| 105 | Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial. BMJ Open, 2015, 5, e007284. | 1.9 | 32 |
| 106 | Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands. Value in Health, 2015, 18, 977-986. | 0.3 | 20 |
| 107 | Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. Value in Health, 2015, 18, 100-109. | 0.3 | 4 |
| 108 | Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 557-559. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values. <i>Value in Health</i> , 2015, 18, 299-307. | 0.3 | 16 |
| 110 | Comparison of EQ-5D and SF-6D utilities in Pompe disease. <i>Quality of Life Research</i> , 2015, 24, 837-844. | 3.1 | 14 |
| 111 | Does registration of performance indicators improve health outcomes in COPD?. , 2015, , . | | 0 |
| 112 | E-monitoring of asthma therapy to improve compliance in children (E-MATIC). , 2015, , . | | 1 |
| 113 | Identifying and explaining the variability in development and implementation costs of disease management programs in the Netherlands. <i>BMC Health Services Research</i> , 2014, 14, 518. | 2.2 | 12 |
| 114 | Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. <i>BMJ</i> , The, 2014, 349, g5392-g5392. | 6.0 | 118 |
| 115 | Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. <i>BMC Pulmonary Medicine</i> , 2014, 14, 163. | 2.0 | 51 |
| 116 | Not Simply More of the Same. <i>Medical Decision Making</i> , 2014, 34, 1048-1058. | 2.4 | 7 |
| 117 | Informal caregiver strain, preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: Results of a randomised controlled trial. <i>International Journal of Nursing Studies</i> , 2014, 51, 1093-1102. | 5.6 | 18 |
| 118 | Cochrane corner: is integrated disease management for patients with COPD effective?: TableÂ1. <i>Thorax</i> , 2014, 69, 1053-1055. | 5.6 | 34 |
| 119 | Exploring the variability of patient costs in disease management programs: a hierarchical modelling approach. <i>Applied Economics</i> , 2014, 46, 940-951. | 2.2 | 5 |
| 120 | Should I Stay or Should I Go Home? A Latent Class Analysis of a Discrete Choice Experiment on Hospital-At-Home. <i>Value in Health</i> , 2014, 17, 588-596. | 0.3 | 39 |
| 121 | Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis. <i>Respiratory Research</i> , 2014, 15, 66. | 3.6 | 63 |
| 122 | Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care. <i>BMC Pulmonary Medicine</i> , 2014, 14, 131. | 2.0 | 13 |
| 123 | Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants. <i>Cost Effectiveness and Resource Allocation</i> , 2014, 12, 17. | 1.5 | 29 |
| 124 | Nutritional assessment and therapy in COPD: a European Respiratory Society statement. <i>European Respiratory Journal</i> , 2014, 44, 1504-1520. | 6.7 | 233 |
| 125 | Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 75. | 2.7 | 26 |
| 126 | Clinical and economic impact of non-adherence in COPD: A systematic review. <i>Respiratory Medicine</i> , 2014, 108, 103-113. | 2.9 | 176 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536. | 0.3 | 41 |
| 128 | The role of disease management programs in the health behavior of chronically ill patients. <i>Patient Education and Counseling</i> , 2014, 95, 137-142. | 2.2 | 23 |
| 129 | Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14021. | 2.6 | 27 |
| 130 | Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2014, 23, 30-37. | 2.3 | 28 |
| 131 | Evidence-based policy making: how cost-effective are disease management programs in the Netherlands?. <i>International Journal of Integrated Care</i> , 2014, 14, . | 0.2 | 0 |
| 132 | Assessing implementation variations of a disease management program in daily practice: the RECODE case study. <i>International Journal of Integrated Care</i> , 2014, 14, . | 0.2 | 0 |
| 133 | The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis. <i>BMC Pulmonary Medicine</i> , 2013, 13, 40. | 2.0 | 47 |
| 134 | RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. <i>BMC Pulmonary Medicine</i> , 2013, 13, 17. | 2.0 | 30 |
| 135 | e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 38. | 3.0 | 32 |
| 136 | An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, e13-e64. | 5.6 | 2,668 |
| 137 | Evaluation of health care providers' role transition and satisfaction in hospital-at-home for chronic obstructive pulmonary disease exacerbations: a survey study. <i>BMC Health Services Research</i> , 2013, 13, 363. | 2.2 | 3 |
| 138 | A Choice That Matters?. <i>Pharmacoeconomics</i> , 2013, 31, 719-730. | 3.3 | 5 |
| 139 | The Role of Value-of-Information Analysis in a Health Care Research Priority Setting. <i>Medical Decision Making</i> , 2013, 33, 472-489. | 2.4 | 7 |
| 140 | Exploring payment schemes used to promote integrated chronic care in Europe. <i>Health Policy</i> , 2013, 113, 296-304. | 3.0 | 68 |
| 141 | Patient preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: Results of a randomised controlled trial. <i>International Journal of Nursing Studies</i> , 2013, 50, 1537-1549. | 5.6 | 36 |
| 142 | Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 353-360.e2. | 2.9 | 263 |
| 143 | Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. <i>European Respiratory Journal</i> , 2013, 41, 556-564. | 6.7 | 9 |
| 144 | Cost-Effectiveness of Early Assisted Discharge for COPD Exacerbations in The Netherlands. <i>Value in Health</i> , 2013, 16, 517-528. | 0.3 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | The Road Not Taken: Transferability Issues in Multinational Trials. <i>Pharmacoeconomics</i> , 2013, 31, 863-876. | 3.3 | 7 |
| 146 | BROADER ECONOMIC EVALUATION OF DISEASE MANAGEMENT PROGRAMS USING MULTI-CRITERIA DECISION ANALYSIS. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 301-308. | 0.5 | 24 |
| 147 | Integrated disease management interventions for patients with chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2013, , CD009437. | 2.8 | 168 |
| 148 | The management of cardiovascular disease in the Netherlands: analysis of different programmes. <i>International Journal of Integrated Care</i> , 2013, 13, e028. | 0.2 | 16 |
| 149 | Early assisted discharge with generic community nursing for chronic obstructive pulmonary disease exacerbations: results of a randomised controlled trial. <i>BMJ Open</i> , 2012, 2, e001684. | 1.9 | 26 |
| 150 | Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2012, 30, 271-302. | 3.3 | 34 |
| 151 | Care delivery pathways for Chronic Obstructive Pulmonary Disease in England and the Netherlands: a comparative study. <i>International Journal of Integrated Care</i> , 2012, 12, e40. | 0.2 | 13 |
| 152 | The potential for integrated care programmes to improve quality of care as assessed by patients with COPD: early results from a real-world implementation study in The Netherlands. <i>International Journal of Integrated Care</i> , 2012, 12, e191. | 0.2 | 15 |
| 153 | Comparing Methods of Data Synthesis. <i>Pharmacoeconomics</i> , 2011, 29, 239-250. | 3.3 | 8 |
| 154 | Utility Estimation in Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2011, 29, 917-932. | 3.3 | 26 |
| 155 | Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2011, 14, 1039-1047. | 0.3 | 30 |
| 156 | Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. <i>New England Journal of Medicine</i> , 2011, 364, 1093-1103. | 27.0 | 603 |
| 157 | Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. <i>Health Policy</i> , 2011, 101, 122-132. | 3.0 | 46 |
| 158 | Is the EQ-5D responsive to recovery from a moderate COPD exacerbation?. <i>Respiratory Medicine</i> , 2011, 105, 1195-1202. | 2.9 | 20 |
| 159 | Tiotropium Reduces Exacerbations Versus Salmeterol Irrespective Of Baseline ICS Treatment In The Poet-COPD; Study. , 2011, , . | | 0 |
| 160 | Seasonal Distribution Of Exacerbations In The Poet-COPD; Study. , 2011, , . | | 0 |
| 161 | Adjusting for COPD severity in database research: developing and validating an algorithm. <i>International Journal of COPD</i> , 2011, 6, 669. | 2.3 | 6 |
| 162 | Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. <i>European Journal of Health Economics</i> , 2011, 12, 397-404. | 2.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Evaluation of a large scale implementation of disease management programmes in various Dutch regions: a study protocol. BMC Health Services Research, 2011, 11, 6. | 2.2 | 37 |
| 164 | Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. European Respiratory Journal, 2011, 37, 508-515. | 6.7 | 152 |
| 165 | Bottom-up implementation of disease-management programmes: results of a multisite comparison. BMJ Quality and Safety, 2011, 20, 76-86. | 3.7 | 13 |
| 166 | Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 68-74. | 2.3 | 21 |
| 167 | Effectiveness and cost-effectiveness of early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the design of a randomised controlled trial. BMC Public Health, 2010, 10, 618. | 2.9 | 25 |
| 168 | Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries. Value in Health, 2010, 13, 230-241. | 0.3 | 26 |
| 169 | If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction, 2010, 105, 1088-1097. | 3.3 | 16 |
| 170 | Association between lung function and exacerbation frequency in patients with COPD. International Journal of COPD, 2010, 5, 435. | 2.3 | 79 |
| 171 | Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax, 2010, 65, 711-718. | 5.6 | 111 |
| 172 | Is INTERdisciplinary COMMunity-based COPD management (INTERCOM) cost-effective?. European Respiratory Journal, 2010, 35, 79-87. | 6.7 | 72 |
| 173 | Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax, 2010, 65, 7-13. | 5.6 | 159 |
| 174 | Application of a theoretical model to evaluate COPD disease management. BMC Health Services Research, 2010, 10, 81. | 2.2 | 17 |
| 175 | Efficacy and Costs of Nutritional Rehabilitation in Muscle-Wasted Patients With Chronic Obstructive Pulmonary Disease in a Community-Based Setting: A Prespecified Subgroup Analysis of the INTERCOM Trial. Journal of the American Medical Directors Association, 2010, 11, 179-187. | 2.5 | 113 |
| 176 | Raising the awareness: projecting the future burden of COPD with the BOLD model. European Respiratory Journal, 2009, 34, 787-789. | 6.7 | 8 |
| 177 | Self-report versus care provider registration of healthcare utilization: Impact on cost and cost-utility. International Journal of Technology Assessment in Health Care, 2009, 25, 588-595. | 0.5 | 19 |
| 178 | An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Advances in Therapy, 2009, 26, 872-885. | 2.9 | 9 |
| 179 | Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health. Pharmacoeconomics, 2009, 27, 465-477. | 3.3 | 33 |
| 180 | PMC4 LARGELY IGNORED: THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR. Value in Health, 2009, 12, A387. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Treatment with inhaled corticosteroids in asthma is too often discontinued. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 411-422. | 1.9 | 42 |
| 182 | Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. <i>Value in Health</i> , 2008, 11, 1070-1080. | 0.3 | 52 |
| 183 | MO3 COMPARING METHODS OF DATA SYNTHESIS: UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL. <i>Value in Health</i> , 2008, 11, A346. | 0.3 | 0 |
| 184 | PRS42 SMOKING-CESSATION ACROSS BORDERS: TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS. <i>Value in Health</i> , 2008, 11, A459. | 0.3 | 0 |
| 185 | PMC7 SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION: IMPACT ON COST AND COST-EFFECTIVENESS. <i>Value in Health</i> , 2008, 11, A561. | 0.3 | 0 |
| 186 | Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. <i>Current Medical Research and Opinion</i> , 2008, 24, 51-61. | 1.9 | 67 |
| 187 | Outcomes for COPD pharmacological trials: from lung function to biomarkers. <i>European Respiratory Journal</i> , 2008, 31, 416-469. | 6.7 | 732 |
| 188 | Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial. <i>International Journal of COPD</i> , 2008, Volume 3, 443-451. | 2.3 | 29 |
| 189 | Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. <i>Current Medical Research and Opinion</i> , 2008, 24, 51-61. | 1.9 | 5 |
| 190 | Cost Consequences of Implementing an Electronic Decision Support System for Ordering Laboratory Tests in Primary Care: Evidence from a Controlled Prospective Study in The Netherlands. <i>Clinical Chemistry</i> , 2007, 53, 213-219. | 3.2 | 40 |
| 191 | A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2007, 25, 695-711. | 3.3 | 30 |
| 192 | Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. <i>European Journal of Health Economics</i> , 2007, 8, 123-135. | 2.8 | 77 |
| 193 | PRS3 COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK:A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD. <i>Value in Health</i> , 2006, 9, A260-A261. | 0.3 | 1 |
| 194 | PRS12 EXPECTED VALUE OF PERFECT INFORMATION: A PRACTICAL EXAMPLE OF REDUCING DECISION UNCERTAINTY BY CONDUCTING ADDITIONAL RESEARCH. <i>Value in Health</i> , 2006, 9, A263-A264. | 0.3 | 0 |
| 195 | PRS18 MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES. <i>Value in Health</i> , 2006, 9, A265-A266. | 0.3 | 0 |
| 196 | Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. <i>Respiratory Medicine</i> , 2006, 100, 83-86. | 2.9 | 63 |
| 197 | Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?. <i>Chest</i> , 2006, 130, 1117-1128. | 0.8 | 177 |
| 198 | Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2006, 7, 86. | 1.9 | 55 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | Economic Modeling in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 630-634. | 3.5 | 31 |
| 200 | Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries. Value in Health, 2005, 8, 32-46. | 0.3 | 95 |
| 201 | Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling Study. Value in Health, 2005, 8, 178-190. | 0.3 | 126 |
| 202 | A dynamic population model of disease progression in COPD. European Respiratory Journal, 2005, 26, 223-233. | 6.7 | 102 |
| 203 | Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis) Tj ETQq1 1 0.784314 rgBT /Overlock 107 2005, 365, 1552-1560. | 13.7 | 621 |
| 204 | MC3 METAMODELLING FORTHE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS. Value in Health, 2005, 8, A1-A2. | 0.3 | 0 |
| 205 | PRS10 PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS. Value in Health, 2005, 8, A214. | 0.3 | 0 |
| 206 | PRS18 DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED BY THE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD SEVERITY STAGES?. Value in Health, 2005, 8, A216-A217. | 0.3 | 0 |
| 207 | One-year cost-effectiveness of tiotropiumversusipratropium to treat chronic obstructive pulmonary disease. European Respiratory Journal, 2004, 23, 241-249. | 6.7 | 118 |
| 208 | Influenza vaccination in asthmatic children: effects on quality of life and symptoms. European Respiratory Journal, 2004, 24, 925-931. | 6.7 | 44 |
| 209 | Influenza Vaccination in Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 488-493. | 5.6 | 131 |
| 210 | Cost Effectiveness of Interventions for Lateral Epicondylitis. Pharmacoeconomics, 2004, 22, 185-195. | 3.3 | 52 |
| 211 | Resource use and risk factors in high-cost exacerbations of COPD. Respiratory Medicine, 2004, 98, 883-891. | 2.9 | 128 |
| 212 | Does influenza vaccination exacerbate asthma in children?. Vaccine, 2004, 23, 91-96. | 3.8 | 28 |
| 213 | Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting. Pharmacoeconomics, 2003, 21, 1103-1112. | 3.3 | 54 |
| 214 | Costs of ankylosing spondylitis in three European countries: the patient's perspective. Annals of the Rheumatic Diseases, 2003, 62, 741-747. | 0.9 | 60 |
| 215 | Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Annals of the Rheumatic Diseases, 2003, 62, 732-740. | 0.9 | 100 |
| 216 | Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Annals of the Rheumatic Diseases, 2002, 61, 429-437. | 0.9 | 182 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | MC3 PROJECTIONS FOR COPD IN THE NETHERLANDS: HOW THE TYPE OF PROJECTION AFFECTS THE ESTIMATED GROWTH IN PREVALENCE. <i>Value in Health</i> , 2002, 5, 455. | 0.3 | 0 |
| 218 | Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 47, 459-467. | 6.7 | 130 |
| 219 | Cost effectiveness of guideline advice for children with asthma: A literature review. <i>Pediatric Pulmonology</i> , 2002, 34, 442-454. | 2.0 | 12 |
| 220 | Resource Use and Costs of Patients With Glaucoma or Ocular Hypertension: A One-year Study Based on Retrospective Chart Review in the Netherlands. <i>Journal of Glaucoma</i> , 2001, 10, 184-191. | 1.6 | 44 |
| 221 | The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. <i>European Respiratory Journal</i> , 2001, 17, 329-336. | 6.7 | 47 |
| 222 | The Impact of Aging and Smoking on the Future Burden of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 590-596. | 5.6 | 190 |
| 223 | The Cost Effectiveness of Early Treatment with Fluticasone Propionate 250 $\hat{1}$ / ₄ g Twice a Day in Subjects with Obstructive Airway Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 2057-2066. | 5.6 | 45 |
| 224 | The Economic Effects of Screening for Obstructive Airway Disease: An Economic Analysis of the DIMCA Program. <i>Preventive Medicine</i> , 2000, 30, 302-308. | 3.4 | 11 |
| 225 | The cost diary. <i>Journal of Clinical Epidemiology</i> , 2000, 53, 688-695. | 5.0 | 293 |
| 226 | Principles of economic evaluation for interventions of chronic musculoskeletal pain. <i>European Journal of Pain</i> , 1999, 3, 343-353. | 2.8 | 28 |
| 227 | Chronic low-back pain: What does cognitive coping skills training add to operant behavioral treatment? Results of a randomized clinical trial.. <i>Journal of Consulting and Clinical Psychology</i> , 1999, 67, 931-944. | 2.0 | 114 |
| 228 | Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. , 1998, 7, 39-51. | | 80 |
| 229 | A Short Term Cost-Effectiveness Model For Oral Antidiabetic Medicines in Europe. <i>Pharmacoeconomics</i> , 1998, 13, 317-326. | 3.3 | 10 |
| 230 | Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma. <i>Pharmacoeconomics</i> , 1998, 14, 671-684. | 3.3 | 33 |
| 231 | A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe. <i>Pharmacoeconomics</i> , 1998, 14, 709-714. | 3.3 | 0 |
| 232 | Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. <i>Health Economics (United Kingdom)</i> , 1998, 7, 39-51. | 1.7 | 3 |
| 233 | Combination of Inhaled Corticosteroids and $\hat{1}$ / ₂ -Agonists in Asthma. <i>BioDrugs</i> , 1996, 6, 489-505. | 0.7 | 5 |
| 234 | Costs and Effects of Inhaled Corticosteroids and Bronchodilators in Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 975-982. | 5.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Economics (United Kingdom), 1994, 3, 333-345. | 1.7 | 101 |
| 236 | Two-Year Bronchodilator Treatment in Patients with Mild Airflow Obstruction. Chest, 1992, 102, 1384-1391. | 0.8 | 63 |